Prediction model for ctDNA detectability in liquid comprehensive genomic profiling of advanced pancreatic cancer based on Japanese real-world data.

ABSTRACT:

Background

Circulating tumor DNA (ctDNA) is sometimes undetectable in liquid comprehensive genomic profiling (CGP) of advanced-stage pancreatic cancer, resulting in false-negative findings that may mislead treatment decisions and waste health care resources. Predicting ctDNA detectability before testing may help optimize the timing of liquid CGP and guide decisions to consider alternative approaches, such as tissue-based CGP.

Patients and methods

We analyzed data from 7498 patients with advanced pancreatic adenocarcinoma using a nationwide real-world clinical genomic database. The tissue CGP cohort (cohort 1) included 4110 patients tested with FoundationOne CDx between June 2019 and December 2023. A prediction model for ctDNA detectability based on routinely available clinic

SUBMITTER: Ikushima H 

PROVIDER: S-EPMC12917527 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature